#Imbed Biosciences #PainGuard #SAM Technology

Imbed Biosciences Launches Innovative SAM™ PainGuard™ for Wound Care

Imbed Biosciences Inc., renowned for its advancements in wound care technology, has introduced SAM™ PainGuard™ with Lidocaine, marking a significant step in improving post-surgical recovery. This product is part of their extensive portfolio of synthetic, antimicrobial, and biocompatible wound matrices. The new PainGuard solution is designed not only for surgical wounds but also targets burn and trauma management through its specialized variants: Surgaflex™ PainGuard™ and Pelashield™ PainGuard™.

The introduction of PainGuard underscores the capabilities of Imbed's SAM™ Antimicrobial Technology platform. This technology effectively fuses several key wound care elements into a single, user-friendly matrix made from bioresorbable polymers. The dual-action nature of this matrix allows it to deliver vital antimicrobial protection while simultaneously addressing acute pain, therefore enhancing the overall wound management process and patient comfort.

In a recent statement, Terry Bromley, CEO of Imbed Biosciences, emphasized the urgency of effective pain management. He mentioned that approximately 90% of patients experience moderate to severe pain following surgical procedures. By addressing this discomfort from the outset, medical professionals can minimize the need for systemic pain medications, including opioids. Such an approach also helps in mitigating long-term complications that can arise from unmanaged pain, like anxiety, PTSD, and prolonged healing times, particularly in burn care scenarios.

Gaurav Pranami, Ph.D., Vice President of Research and Development at Imbed, shared insights regarding the development of PainGuard, highlighting the integration of lidocaine and silver within the matrix.